- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01807988
Internetbased Relapse Prevention for Partially Remitted Depression (ISAK)
January 22, 2014 updated by: Fredrik Holländare, Örebro County Council
Regional Study of Internet-based Relapse Prevention as an Adjunct to Partially Successful Antidepressant Medication
The main purpose of the study is to test whether Internet-based relapse prevention plus medication has a better protective effect compared to medication only, for persons with residual depressive symptoms who are currently in paid employment or in education. We hypothesise that during the two years following the intervention:
- The persons in the group receiving Internet-based relapse prevention plus medication will be absent from work for fewer days due to sick-leave compared to those in the medication-only group.
- Fewer persons in the group receiving Internet-based relapse prevention + medication will experience long term sick-leave (60 days or more) compared to those in the medication-only group.
- The persons in the group receiving Internet-based relapse prevention plus medication will suffer fewer depressive relapses compared to those in the medication-only group.
- At follow-up, the persons in the group receiving Internet-based relapse prevention plus medication will have higher health related quality of life and lower levels of depressive symptoms compared to those in the medication-only group.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
264
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Uppsala, Sweden, 751 85
- Recruiting
- Psychiatric Clinic in Uppsala
-
Contact:
- Lisa Ekselius, PhD
- Email: Lisa.Ekselius@neuro.uu.se
-
Örebro, Sweden, 70116
- Not yet recruiting
- Psychiatric Research Centre
-
Contact:
- Fredrik Holländare, PhD
- Phone Number: +46737600700
- Email: fredrik.hollandare@orebroll.se
-
Principal Investigator:
- Fredrik Holländare, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Mild residual depressive symptoms (7-19 on the MADRS-S).
- A history of at least one episode of Major Depression.
- Currently in (at least) half-time employment, self-employment or education.
- Taking a stable (since one month) and therapeutic dosage of antidepressant medication
- Being able to read and write Swedish
- Having access to the internet
Exclusion Criteria:
- Fulfilling the criteria for Major depression
- Psychosis
- Substance abuse
- Suicidality
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: iCBT
Internetbased cognitive behavior therapy (iCBT) aimed att preventing relapse into major depression.
|
Internetbased cognitive behavior therapy (iCBT) contains interventions that will help the participant to change her behavior to experience more positive reinforcement in daily life and also to challenge her negative patterns of thought.
There are also information and exercices to improve sleep, increase physical activity, train mindfulness, handle anxiety and to learn about depression.
|
|
No Intervention: Control group
The control group in the study will fill out questionnaires every month and will be interviewed every month to detect any relapses.
They will also receive feedback on there self-reported symptoms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Days absent from work due to sick leave
Time Frame: 24 month follow up
|
The total number of days that a participant has been absent from work due to sick leave (any cause).
Data will be collected from the National Insurance Agency at the end of the study.
|
24 month follow up
|
|
Change in self-reported sick leave days
Time Frame: After 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 months
|
Self-reported number of sick leave days during the study will be collected cumulatively every month during the study time and summarised after 24 months.
|
After 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 months
|
|
Change in diagnostic status
Time Frame: After 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 months
|
Change in diagnostic status (depressive relapse) will be assessed in a telephone interview every month during the study.
The definition of a relapse is to fulfill the diagnostic criteria for major depression according to the DSM-IV at any time after the study start.
|
After 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 months
|
|
Change in depressive symptoms
Time Frame: After 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 months
|
Change in depressive symptoms will be measured by an internetbased version of the Montgomery-Asberg Depression Rating Scale - Self rated.
The patient will fill out the questionnaire every month.
|
After 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in health related quality of life
Time Frame: After 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 months
|
Health related quality of life will be measured by an internetbased version of the EQ-5D.
The questionnaire will be filled out every month.
|
After 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 months
|
|
Change in costs associated with illness
Time Frame: Pre- and post treatment, after 12 and 24 months
|
Change in costs will be measured by an internetbased version of the self-assessment scale Trimbos/iMTA questionnaire on Costs associated with Psychiatric illness (TIC-P).
|
Pre- and post treatment, after 12 and 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2013
Primary Completion (Anticipated)
December 1, 2014
Study Completion (Anticipated)
December 1, 2014
Study Registration Dates
First Submitted
March 6, 2013
First Submitted That Met QC Criteria
March 7, 2013
First Posted (Estimate)
March 8, 2013
Study Record Updates
Last Update Posted (Estimate)
January 23, 2014
Last Update Submitted That Met QC Criteria
January 22, 2014
Last Verified
January 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012/488
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.